A prescription medicine used to treat gout is suspected to have caused 10 deaths in the nation over the past eight years due to side effects that can sometimes be severe, the Food and Drug Administration (FDA) said yesterday.
Colchicine, a strong anti-inflammatory that is widely used to treat gout, has been used in the nation for nearly 40 years and is one of the available options for the frontline treatment of people with gout.
A total of 17 colchicine products have been licensed by the FDA and about 38 million colchicine tablets are sold in the nation each year, the FDA said.
However, from 2011 to August this year, the FDA received 353 reports suggesting adverse reactions to the drug, mostly among patients with renal and liver dysfunction, with 10 deaths believed to be linked to the problem.
Serious side effects of colchicine include blood disease, muscle weakness and neuropathy, said Hung Kuo-teng (洪國登), head of the Medicinal Products Division.
People with renal or hepatic impairment and those who also take other drugs for chronic diseases could experience serious side effects from colchicine, Hung said.
Colchicine is used to relieve the pain and swelling of an acute gout episode and people who experience acute gout attacks usually take the drug for five to seven days.
People with frequent acute flare-ups or chronic gout tend to use it on a long-term basis, said Chen Ming-han (陳明翰), an attending physician at Taipei Veterans General Hospital’s Division of Allergy, Immunology and Rheumatology.
Because of the side effects, doctors tend to prescribe low-dose colchicine for people with renal or hepatic impairment, he said.
Two other medications for gout — benzbromarone and febuxostat — might also increase the risk of side effects, he said.
In Japan, Europe and the US, there have been reports of patients dying of renal failure after using benzbromarone, Chen said.
CARGO LOSS: About 50 containers at the stern of the ‘Ever Lunar’ cargo ship went overboard, prompting the temporary closure of the port and disrupting operations Evergreen Marine Corp, Taiwan’s largest container shipper, yesterday said that all crew members aboard the Ever Lunar (長月) were safe after dozens of containers fell overboard off the coast of Peru the previous day. The incident occurred at 9:40am on Friday as the Ever Lunar was anchored and waiting to enter the Port of Callao when it suddenly experienced severe rolling, Evergreen said in a statement. The rolling, which caused the containers to fall, might have been caused by factors including a tsunami triggered by an earthquake in Russia, poor winter sea conditions in South America or a sudden influx of waves,
The Ministry of Culture yesterday officially launched the “We TAIWAN” cultural program on Osaka’s Nakanoshima sandbank, with the program’s mascot receiving overwhelming popularity. The cultural program, which runs from Aug. 2 to 20, was designed to partner with and capitalize on the 2025 World Expo that is being held in Osaka, Japan, from April 13 to Oct. 13, the ministry said. On the first day of the cultural program, its mascot, a green creature named “a-We,” proved to be extremely popular, as its merch was immediately in high demand. Long lines formed yesterday for the opening
The Taipei Summer Festival is to begin tomorrow at Dadaocheng Wharf (大稻埕), featuring four themed firework shows and five live music performances throughout the month, the Taipei Department of Information and Tourism said today. The festival in the city’s Datong District (大同) is to run until Aug. 30, holding firework displays on Wednesdays and the final Saturday of the event. The first show is scheduled for tomorrow, followed by Aug. 13, 20 and 30. To celebrate the 30th anniversary of Disney Pixar's movie Toy Story, the festival has partnered with Walt Disney Co (Taiwan) to host a special themed area on
BE CAREFUL: The virus rarely causes severe illness or death, but newborns, older people and those with medical conditions are at risk of more severe illness As more than 7,000 cases of chikungunya fever have been reported in China’s Guangdong Province this year, including 2,892 new cases last week, the Centers for Disease Control (CDC) yesterday said it is monitoring the situation and considering raising the travel notice level, which might be announced today. The CDC issued a level 1 travel notice, or “watch,” for Guangdong Province on July 22, citing an outbreak in Foshan, a manufacturing hub in the south of the province, that was reported early last month. Between July 27 and Saturday, the province reported 2,892 new cases of chikungunya, reaching a total of 7,716
RSS